Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Operating Income: 2011-2025

Historic Operating Income for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to -$1.1 million.

  • Sunshine Biopharma's Operating Income rose 1.78% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 31.80%. This contributed to the annual value of -$5.8 million for FY2024, which is 21.46% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Operating Income of -$1.1 million as of Q3 2025, which was up 47.11% from -$2.1 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Operating Income peaked at -$279,631 during Q4 2021, and registered a low of -$23.4 million during Q4 2022.
  • For the 3-year period, Sunshine Biopharma's Operating Income averaged around -$1.4 million, with its median value being -$1.3 million (2024).
  • As far as peak fluctuations go, Sunshine Biopharma's Operating Income slumped by 8,255.16% in 2022, and later skyrocketed by 94.92% in 2023.
  • Sunshine Biopharma's Operating Income (Quarterly) stood at -$279,631 in 2021, then crashed by 8,255.16% to -$23.4 million in 2022, then skyrocketed by 94.92% to -$1.2 million in 2023, then crashed by 71.64% to -$2.0 million in 2024, then rose by 1.78% to -$1.1 million in 2025.
  • Its Operating Income was -$1.1 million in Q3 2025, compared to -$2.1 million in Q2 2025 and -$1.3 million in Q1 2025.